@willxue123
Well in the recent OPT update you got the answer in the fine print
Note: Additional funding will be required to reach commercialization of sozinibercept and to meet obligations under the Development Funding Agreement ("DFA"). As a result of obligations under the DFA and applicable law regarding liquidity, the Company expects toraise or obtain additional capital in one or more transactions,earlier than 3Q CY 2025or anticipated topline data readout dates.
Interesting negative implications for the OPTOB and even OPTOA pricing.
So that is at odds with them saying the recent funding was enough to see them through both topline readout dates. Wondering what OPT specifically means. I was of the understanding that additional funding would be required for realize commercialization. Not before.
@willxue123Well in the recent OPT update you got the answer in...
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
87.3¢ |
Change
-0.008(0.85%) |
Mkt cap ! $1.077B | |||
| Open | High | Low | Value | Volume |
| 88.0¢ | 88.0¢ | 86.5¢ | $1.226M | 1.402M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 37 | 113722 | 87.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 87.5¢ | 69717 | 37 |
View Market Depth
| Last trade - 14.04pm 09/10/2024 (20 minute delay) ? |
| OPT (ASX) Chart |